TARGET TERAPIYA TA’SIRIDA O‘TKIR LIMFOBLAST LEYKEMIYADA SHAKLLANUVCHI MOLEKULYAR VA HUJAYRAVIY REZISTENTLIK MEXANIZMLAR

Xaqqulova Marta Alisherovna

TDTU Normal va Patologik fiziologiya kafedrasi asisstenti

Rahmonova Umida Tohir qizi

Toshkent Davlat tibbiyot Unversiteti talabasi

Abdumannonova Xidoyatxon G‘anisher qizi

Toshkent Davlat tibbiyot Unversiteti talabasi

Keywords: O‘tkir limfoblast leykemiya, target terapiya, tirozin kinaza ingibitorlari, molekulyar rezistentlik, hujayraviy mexanizmlar, BCR-ABL1 mutatsiyasi, signal yo‘llari.

---

Abstract

Ushbu maqolada o‘tkir limfoblast leykemiya (OLL)da qo‘llaniladigan target (maqsadli) terapiya vositalarining molekulyar ta’sir mexanizmlari hamda organizmda dori rezistentligining shakllanish jarayonlari tahlil qilingan. Hujayra ichidagi signal yo‘llari, genetik mutatsiyalar va mikroatmosfera o‘zgarishlari asosida rezistentlikning rivojlanish sabablari yoritilgan. Shuningdek, target terapiyaga nisbatan ikkilamchi chidamlilikni yengish bo‘yicha zamonaviy strategiyalar muhokama etilgan.

---

References

1. Pui C.H., Evans W.E. Treatment of Acute Lymphoblastic Leukemia. N Engl J Med, 2006; 354(2): 166–178.

2. Jabbour E., Kantarjian H. Chronic Myeloid Leukemia and Resistance to Tyrosine Kinase Inhibitors. Blood, 2020; 135(21): 1624–1631.

3. Konopleva M., et al. Mechanisms of Resistance to BCL-2 Inhibition in Leukemia. Blood, 2022; 140(10): 1125–1138.

4. Zhou J., et al. Microenvironment-Mediated Drug Resistance in Acute Lymphoblastic Leukemia. Front Oncol, 2021; 11: 636251.

5. Burger J.A., Peled A. CXCR4 Antagonists in Leukemia Therapy. Leukemia, 2009; 23: 43–52.

6. Cortes J., et al. Ponatinib in Refractory Philadelphia Chromosome-Positive ALL. J Clin Oncol, 2019; 37(5): 400–407.